The effects of nepafenac and amfenac on retinal angiogenesis

Brain Research Bulletin

Volumn 81, Issue 2-3, 2010, Pages 310-319

  Yanni, Susan E ^a   Clark, Monika L ^a   Yang, Rong ^a   Bingaman, David P ^b   Penn, John S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

COX 2; Endothelial cells; M ller cells; NSAID; Oxygen induced retinopathy; Retinal angiogenesis; Therapeutics

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; AMFENAC; CELECOXIB; CYCLOOXYGENASE 1; DICLOFENAC; KETOROLAC; KETOROLAC TROMETAMOL; MESSENGER RNA; NEPAFENAC; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE B2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RAT; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; SINGLE DRUG DOSE;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; NEUROGLIA; OXYGEN; PHENYLACETATES; PROSTAGLANDINS; PYRAZOLES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73149083236     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.10.018     Document Type: Article

References (105)

1. Abran D., Dumont I., Hardy P., et al. Characterization and regulation of prostaglandin E2 receptor and receptor-coupled functions in the choroidal vasculature of the pig during development. Circ. Res. 80 (1997) 463-472
2. Abran D., Varma D.R., and Chemtob S. Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs. Am. J. Physiol. 272 (1997) R995-R1001
3. Abran D., Varma D.R., Li D.-Y., et al. Reduced responses of retinal vessels of the newborn pig to prostaglandins but not to thromboxane. Can. J. Physiol. Pharmacol. 72 (1994) 168-173
4. Aiello L.P., Northrup J.M., Keyt B.A., et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalomol. 113 (1995) 1538-1544
5. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10457-10461
6. Akarasereenont P.C., Techatraisak K., Thaworn, et al. The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm. 11 (2002) 17-22
7. Amrite A.C., Ayalasomayajula S.P., Cheruvu N.P.S., et al. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47 (2006) 1149-1160
8. Amrite A.C., and Kompella U.B. Celecoxib inhibits proliferation of retinal pigment epithelial cells and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J. Pharmacol. Exp. Ther. 324 (2008) 749-758
9. Asikainen T.M., Heikkila P., Kaarteenaho-Wiik R., et al. Cell-specific expression of manganese superoxide dismutase protein in the lungs of patients with respiratory distress syndrome, chronic lung disease, or persistent pulmonary hypertension. Pediatr. Pulmonol. 32 (2001) 193-200
10. Ayalasomayajula S.P., and Kompella U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharm. 511 (2005) 191-198
11. Barnett J.M., McCollum G.W., Fowler J.A., et al. Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Invest. Ophthalmol. Vis. Sci. 28 (2007) 907-915
12. Barnett J.M., McCollum G., and Penn J.S. The role of cytosolic phospholipase A2 in retinal neovascularization. Invest. Ophthalmol. Vis. Sci. (2009) (Epub ahead of print)
13. Berkowitz B.A., Roberts R., Luan H., et al. Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2954-2960
14. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1432-1444
15. Burnette J.O., and White R.E. PGI2 opens potassium channels in retinal pericytes by cyclic AMP-stimulated, cross-activation of PKG. Exp. Eye Res. 83 (2006) 1359-1365
16. Casey R., and Li W.W. Factors controlling ocular angiogenesis. Am. J. Ophthalmol. 124 (1997) 521-529
17. Chemtob S., Beharry K., Rex J., et al. Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets. Invest. Ophthalmol. Vis. Sci. 32 (1991) 1799-1807
18. Cheng T., Cao W., Wen R., et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest. Ophthalmol. Vis. Sci. 39 3 (1998) 581-591
19. Chiarugi V., Magnelli L., and Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int. J. Mol. Med. 2 (1998) 715-719
20. Cryan L.M., Pidgeon G.P., Fitzgerald D.J., et al. COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. Mol. Vis. 12 (2006) 405-414
21. D'Amore P.A. Mechanisms of retinal and choroidal angiogenesis. Invest. Ophthalmol. Vis. Sci. 35 (1994) 3974-3979
22. Daikoku T., Wang D., Tranguch S., et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65 (2005) 3735-3744
23. Daniel T.O., et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial cell migration and angiogenesis. Cancer Res. 59 (1999) 4574-4577
24. Diaz-Flores L., Gutierrez R., and Varela H. Angiogenesis: an update. Histol. Histopathol. 9 4 (1994) 807-843
25. Dumont I., Hardy P., Peri K.G., et al. Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid. Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H60-66
26. Flower R.W., McLeod D.S., Wajer S.D., et al. Prostaglandins as mediators of vasotonia in the immature retina. Pediatrics 73 (1984) 440-444
27. Form D.M., and Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172 (1983) 214-218
28. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 143 (2007) 566-583
29. Gamache D.A., Graff G., Brady M.T., et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. I. Assessment of anti-inflammatory efficacy. Inflammation 24 4 (2000) 357-370
30. Gierse J.K., Koboldt C.M., Walker M.C., et al. Kinetic basis for selective inhibition of cylco-oxygenases. Biochem. J. 339 (1999) 607-614
31. Gullino P.M. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol. 34 (1995) 439-441
32. Gupta R.A., Tejada L.V., Tong B.J., et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63 (2003) 906-911
33. Han R.N., Babaei S., Robb M., et al. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia?. Circ Res. 94 (2004) 1115-1123
34. Hardy P., Abran D., Li D.Y., et al. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins. Invest. Ophthalmol. Vis. Sci. 35 (1994) 580-591
35. Hardy P., Bhatthacharya M., Abran D., et al. Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-1 and -2 inhibition. Invest. Ophthalmol. Vis. Sci. 39 (1998) 1888-1898
36. Hardy P., Dumont I., Bhattacharya M., et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc. Res. 47 (2000) 489-509
37. Hardy P., Peri K.G., Lahaie I., et al. Increased nitric oxide synthesis and action preclude choroidal vasoconstriciton to hyperoxia in newborn pigs. Circ. Res. 79 (1996) 504-511
38. Hariprasad S.M., Callanan D., Gainey S., et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J. Ocul. Pharmacol. Ther. 23 (2007) 585-589
39. Hicks D., and Curtois Y. The growth and behaviour of rat retinal Müller cells in vitro. 1. An improved method for isolation and culture. Exp. Eye Res. 51 (1990) 119-129
40. Joussen A.M., Poulaki V., Qin W., et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16 (2002) 438-440
41. Kaiser P.K., Blodi B.A., Shapiro H., et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114 (2007) 1868-1875
42. Kapin M.A., Yanni J.M., Brady M.T., et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 27 5 (2003) 281-291
43. Katz M.L., and Robison Jr. W.G. Autoxidative damage to the retina: potential role in retinopathy of prematurity. Birth Defects Orig. Artic. Ser. 24 (1988) 237-248
44. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58 (1998) 409-412
45. Ke T.-L., Graff G., Spellman J.M., et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. II. In vitro bioactivation and permeation of ocular barriers. Inflammation 24 4 (2000) 371-384
46. Kern T.S., Miller C.M., and Du Y. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56 (2007) 373-379
47. Lane S.S., Modi S.S., Lehmann R.P., et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J. Cataract Refract. Surg. 33 1 (2007) 53-58
48. Leahy K.M., Ornberg R.L., and Wang Y. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62 3 (2002) 625-631
49. Lee P., Wang C.C., and Adamis A.P. Ocular neovascularization: an epidemiologic review. Surv. Opthalmol. 43 3 (1998) 245-269
50. Li W., Xu R.J., Lin Z.Y., et al. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med. Oncol. (2008) (Epub ahead of print)
51. Lukiw W.J., Ottlecz A., Lambrou G., et al. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4163-4170
52. MacRitchie A.N., Albertine K.H., Sun J., et al. Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (2001) L1011-1020
53. Masferrer J.L., Leahy K.M., and Koki A.T. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 5 (2000) 1306-1311
54. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 112 (2001) RE21
55. Murphy J.F., and Fitzgerald D.J. Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependent proliferation of endothelial cells (EC) via the VEGF-2 receptor. FASEB J. 15 (2001) 1667-1669
56. 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. 267 (2000) 245-251
57. Niesman M.R., Johnson K.A., and Penn J.S. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem. Res. 22 (1997) 597-605
58. Ortéga N., Hutchings H., and Plouët J. Signal relays in the VEGF system. Front. Biosci. 4 (1999) 141-152
59. 2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 286 5 (2001) 923-928
60. Penn J.S. Oxygen-induced retinopathy in the rat: possible contribution of peroxidation reactions. Doc. Ophthalmol. 74 (1990) 179-186
61. Penn J.S., Henry M.M., and Tolman B.L. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr. Res. 26 6 (1994) 724-731
62. Penn J.S., Tolman B.L., and Bullard L.E. Effect of a water-soluble vitamin E analog, trolox C, on retinal vascular development in an animal model of retinopathy of prematurity. Free Radic. Biol. Med. 22 (1997) 977-984
63. Penn J.S., Tolman B.L., and Henry M.M. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest. Ophthalmol. Vis. Sci. 35 (1994) 3429-3435
64. Penn J.S., Tolman B.L., and Lowery L.A. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest. Ophthalmol. Vis. Sci. 34 (1993) 576-585
65. Penn J.S., Thum L.A., and Naash M.I. Oxygen-induced retinopathy in the rat. Vitamins C and E as potential therapies. Invest. Ophthalmol. Vis. Sci. 33 (1992) 1836-1845
66. Pierce E.A., Avery R.L., Foley E.D., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5510-5514
67. 2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 62 (2002) 63-66
68. Quiniou C., Sennlaub F., Beauchamp M.H., et al. Dominant role for calpain in thromboxane-induced neuromicrovascular endothelial cytotoxicity. J. Pharmacol. Exp. Ther. 316 (2006) 618-627
69. Rahmani B., Tielsch J.M., Kat J., et al. The cause-specific prevalence of visual impairment in an urban population. The Baltimore eye survey. Ophthalmology 103 (1996) 1721-1726
70. Raju T.N., Langenberg P., Bhutani V., et al. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J. Pediatr. 131 (1997) 844-850
71. Recchia FM, Xu L, Penn JS, et al. Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest. Ophthalmol. Vis. Sci.; 2009 October 15. [Epub ahead of print].
72. Regillo C.D., Brown D.M., Abraham P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 145 (2008) 239-248
73. Robbins S.G., Conaway J.R., Ford B.L., et al. Detection of VEGF protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Growth Factors 14 (1997) 229-241
74. Robbins S.G., Rajaratnam V.S., and Penn J.S. Evidence for upregulation and redistribution of VEGF receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors 16 (1998) 1-9
75. Rodieck R.W. The Vertebrate Retina: Principles of Structure and Function (1973), San Francisco, WH Freeman p. 159
76. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1419-1431
77. Sabbieti M.G., Marchetti L., Gabrielli M.G., et al. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res. 319 (2005) 267-278
78. Saito Y., Geisen P., Uppal A., et al. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol. Vis. 13 (2007) 840-853
79. Sales K.J., Boddy S.C., Williams A.R., et al. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 148 (2007) 3635-3644
80. Sales K.J., Katz A.A., Howard B., et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 62 (2002) 424-432
81. Sano H., Noguchi T., Miyajima A., et al. Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 3068-3072
82. Satarug S., Wisedpanichkij R., Takeda K., et al. Prostaglandin D2 induces heme oxygenase-1 mRNA expression through the DP2 receptor. Biochem. Biophys. Res. Commun. 377 (2008) 878-883
83. Sawaoka H., Tsuji S., Tsuji M., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 79 12 (1999) 1469-1477
84. Sennlaub F., Valamanesh F., Vazquez-Tello A., et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108 (2003) 198-204
85. Smith C.J., Zhang Y., Koboldt C.M., et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13313-13318
86. Steinkuller P.G., Du L., Gilbert C., et al. Childhood blindness. J. AAPOS 3 (1999) 26-32
87. Sun Y., Chen J., and Rigas B. Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 30 (2009) 93-100
88. Takahashi K., Saishin Y., Saishin Y., et al. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 44 1 (2003) 409-415
89. Takahashi H., Yanagi Y., Tamaki Y., et al. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem. Biophys. Res. Commun. 325 (2004) 461-466
90. Thieme H., Aiello L.P., Takagi H., et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44 (1995) 98-103
91. van Rossum G.S., Drummen G.P., Verkleij A.J., et al. Activation of cytosolic phospholipase A2 in Her14 fibroblasts by hydrogen peroxide: a p42/44(MAPK)-dependent and phosphorylation-independent mechanism. J. Biochim. Biophys. Acta 1636 (2004) 183-195
92. von Rahden B.H., Stein H.J., Pühringer F., et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 65 (2005) 5038-5044
93. Walters T., Raizman M., Ernest P., et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J. Cataract Refract. Surg. 33 (2007) 1539-1545
94. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. PNAS 96 (1999) 7563-7568
95. Werdich X.Q., McCollum G.W., Rajaratnam V.S., and Penn J.S. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp. Eye Res. 79 (2004) 623-630
96. Wilkinson-Berka J.L., Alousis N.S., Kelly D.J., et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 44 3 (2003) 974-979
97. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18 (1999) 7908-7916
98. Wu G., Luo J., Rana J.S., et al. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc. Res. 69 (2006) 512-519
99. Yamada M., Kawai M., Kaway Y., et al. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 19 4 (1999) 300-304
100. Yanni S.E., Barnett J.M., Clark M.L., et al. PGE2 receptor EP4 is a potential therapeutic target for the treatment of pathological ocular angiogenesis. Invest. Ophthalmol. Vis. Sci. (2009) (Epub ahead of print)
101. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49 (2001) 568-581
102. Zhu Y., Park T.S., and Gidday G.M. Mechanisms of hyperoxia-induced reductions in retinal blood flow in newborn pig. Exp. Eye Res. 67 (1998) 357-369
103. Ziche M., Jones J., and Gullino P.M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69 (1982) 475-482
104. Wang FE, et al. IOVS 2004; 45:ARVO E-Abstract 3711.
105. Hariprasad SM, et al. IOVS 2009:50:ARVO E-Abstract 5999.